Mark Louis Friedman - 16 Mar 2022 Form 4 Insider Report for Axogen, Inc. (AXGN)

Reporting relationship: VP Regulatory Affairs & Policy
Issuer ticker: AXGN
Reported as of: 16 Mar 2022
Net transaction value: -$11,971
SEC form: 4
Accepted by SEC: 18 Mar 2022, 16:06:56 UTC
Prior SEC filing: 17 Feb 2022
Source filing: View source filing
Reporting owner signature: /s/Mark Friedman

Key filing fact

Mark Louis Friedman filed Form 4 for Axogen, Inc. (AXGN) on 18 Mar 2022.

Key facts

This page summarizes Mark Louis Friedman's Form 4 filing for Axogen, Inc. (AXGN).
5 reported transactions and 3 derivative rows are listed below.
Accepted by SEC: 18 Mar 2022, 16:06.

Change

Previous filing in this sequence was filed on 17 Feb 2022.
Current net transaction value: -$11,971.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

AXGN transaction

Common Stock

Options Exercise

Transaction value: $0
Shares: +6,000
Change %: +30%
Price: $0.000000
Shares after: 25,845
Date: 16 Mar 2022
Ownership: Direct
Footnotes: F1

AXGN transaction

Common Stock

Tax liability

Transaction value: $11,971
Shares: -1,502
Change %: -5.8%
Price: $7.97
Shares after: 24,343
Date: 16 Mar 2022
Ownership: Direct
Footnotes: F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

AXGN transaction Derivative

Restricted Stock Units

Options Exercise

Transaction value: $0
Shares: -6,000
Change %: -50%
Price: $0.000000
Shares after: 6,000
Date: 16 Mar 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 6,000
Exercise price
Footnotes: F3, F4

AXGN transaction Derivative

Restricted Stock Units

Award

Transaction value: $0
Shares: +35,829
Change %
Price: $0.000000
Shares after: 35,829
Date: 16 Mar 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 35,829
Exercise price
Footnotes: F3, F5

AXGN transaction Derivative

Employee Stock Option (right to purchase)

Award

Transaction value: $0
Shares: +33,419
Change %
Price: $0.000000
Shares after: 33,419
Date: 16 Mar 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 33,419
Exercise price: $8.20
Footnotes: F6

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

Mark Louis Friedman is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 6 footnotes

Footnote F1

This reflects the number of restricted stock units that became vested as of March 16, 2022.

Footnote F2

Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

Footnote F3

Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.

Footnote F4

All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2024 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2022 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date.

Footnote F5

All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2026 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregateshares vest on March 16, 2024 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date.

Footnote F6

All shares of Axogen, Inc. common stock underlying the employee stock option will be fully vested on March 16, 2026 (4 years from the option grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2024 (24 months from the option grant date) and an additional 12.5% of the aggregate shares vest each 6 months thereafter.